Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/10/2025

Radiation Pneumonitis Management

Diagnosis and Assessment

  • Radiation pneumonitis typically occurs 2-6 months after radiotherapy completion, presenting with nonproductive cough, exercise-induced dyspnea, low-grade fever, and chest pain 2, 3
  • Differential diagnosis should include pulmonary infections, COPD exacerbations, heart failure, and immunotherapy-induced lung changes, which account for approximately 45% of post-radiation respiratory symptoms 3, 4
  • Bronchoscopy with bronchoalveolar lavage is recommended in grade 2 or higher pneumonitis to rule out infection before initiating immunosuppressive therapy 1

Treatment Algorithm Based on Severity

  • Initiate oral prednisone 1 mg/kg daily or equivalent for grade 1-2 pneumonitis 1, 2
  • Hospitalize patient immediately and initiate high-dose intravenous corticosteroids (methylprednisolone 2-4 mg/kg/day) for grade 3-4 pneumonitis 1, 3
  • Delay reintroduction of immunotherapy (if applicable) until prednisone dose is ≤10 mg daily 1
  • Permanently discontinue the immunotherapy treatment if it was the cause 1

Supportive Care

  • Provide symptomatic treatment with inhaled β2-mimetics and oxygen supplementation as needed 2, 3
  • Consider prophylactic antibiotics for Pneumocystis pneumonia in patients receiving prolonged corticosteroid therapy (≥20 mg prednisone daily for ≥4 weeks) 5
  • Add calcium and vitamin D supplementation with prolonged steroid use 5
  • Encourage smoking cessation, which is associated with decreased cough and dyspnea 2, 3

Monitoring and Follow-up

  • Assess patients clinically every 2-3 days initially for grade 2 pneumonitis 1
  • Monitor weekly with history, physical examination, and pulse oximetry 5
  • Perform repeat chest imaging in 3-4 weeks or sooner if symptoms worsen 5
  • Taper steroids very slowly and carefully over 6 weeks or more, as relapses during tapering have been reported 1

Special Considerations

  • Patients with pre-existing interstitial lung disease require more intensive monitoring and counseling about their elevated risk 2, 6
  • The mean lung dose (MLD) and V20 (percentage of lung volume receiving ≥20 Gy) correlate with pneumonitis risk; V20 of 35-37% or MLD of 20-23 Gy are considered upper limits 6, 7